
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About
Avalon GloboCare Corp. (ALBT)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ALBT (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $0
1 Year Target Price $0
0 | Strong Buy |
0 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -73.42% | Avg. Invested days 55 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.93M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.02 | 52 Weeks Range 2.11 - 11.66 | Updated Date 06/29/2025 |
52 Weeks Range 2.11 - 11.66 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -8.01 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -243.34% |
Management Effectiveness
Return on Assets (TTM) -23.8% | Return on Equity (TTM) -833.99% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 25157592 | Price to Sales(TTM) 7.34 |
Enterprise Value 25157592 | Price to Sales(TTM) 7.34 | ||
Enterprise Value to Revenue 18.38 | Enterprise Value to EBITDA -4.45 | Shares Outstanding 2132240 | Shares Floating 1451691 |
Shares Outstanding 2132240 | Shares Floating 1451691 | ||
Percent Insiders 23.35 | Percent Institutions 0.83 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Avalon GloboCare Corp.
Company Overview
History and Background
Avalon GloboCare Corp. (ALBT) is a biopharmaceutical company founded to develop and commercialize innovative exosome technologies and cellular therapeutics. The company aims to address unmet medical needs in cancer, infectious diseases, and autoimmune disorders. It was founded in 2017.
Core Business Areas
- Exosome Technology: Develops and utilizes its Avalon Stem-Cell derived Exosomes (ASTEX) platform for therapeutic applications, including drug delivery and regenerative medicine.
- Cellular Immunotherapy: Focuses on developing cellular immunotherapies, including CAR-T cell therapies, to target and eliminate cancer cells.
- Drug Delivery: Developing technologies to deliver therapeutics directly to target cells, enhancing efficacy and reducing side effects.
Leadership and Structure
David Jin is the President and CEO. The company operates with a scientific advisory board and a management team focused on research and development, clinical trials, and commercialization.
Top Products and Market Share
Key Offerings
- ASTEX Platform: Avalon Stem-Cell derived Exosomes (ASTEX) is the company's core technology platform. Market share data is not readily available for this specific platform. Competitors in exosome therapeutics include companies like Codiak BioSciences (CDAK, now defunct) and Evox Therapeutics.
- CAR-T Cell Therapy Programs: Avalon is developing CAR-T cell therapies for various cancers. Market share information is not publicly disclosed for Avalon's specific CAR-T programs. Major competitors in the CAR-T cell therapy field include Novartis (Kymriah), Gilead Sciences (Yescarta), and Bristol Myers Squibb (Breyanzi).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, regulatory hurdles, and intense competition. The fields of exosome technology and cellular immunotherapy are rapidly growing with significant potential for treating a wide range of diseases.
Positioning
Avalon GloboCare Corp. positions itself as an innovator in exosome-based therapeutics and cellular immunotherapy, focusing on developing novel technologies and therapies for unmet medical needs. Competitive advantages include their proprietary ASTEX platform and their focus on specific cancer targets.
Total Addressable Market (TAM)
The global exosome market is expected to reach billions of dollars in the coming years, and the CAR-T cell therapy market is also projected to experience substantial growth. Avalon is positioned to capture a share of these markets with its innovative technologies.
Upturn SWOT Analysis
Strengths
- Proprietary ASTEX platform technology
- Focus on innovative exosome and cellular therapies
- Experienced leadership team
- Strategic partnerships
Weaknesses
- Limited financial resources
- Dependence on key personnel
- Early stage of development
- High risk of clinical trial failures
Opportunities
- Growing demand for exosome and cellular therapies
- Potential for strategic alliances and collaborations
- Expansion into new therapeutic areas
- Increasing awareness and acceptance of personalized medicine
Threats
- Intense competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Technological advancements by competitors
- Market volatility and economic downturn
Competitors and Market Share
Key Competitors
- NVS
- GILD
- BMY
- CRSP
- EDIT
Competitive Landscape
Avalon faces significant competition from larger, more established pharmaceutical companies with greater resources. Its success depends on its ability to develop and commercialize innovative technologies.
Growth Trajectory and Initiatives
Historical Growth: Avalon's historical growth has been characterized by periods of rapid expansion followed by financial difficulties.
Future Projections: Future growth projections are highly uncertain and dependent on successful clinical trials, regulatory approvals, and securing additional funding.
Recent Initiatives: Recent initiatives include focusing on its exosome platform technology, restructuring operations, and seeking strategic partnerships.
Summary
Avalon GloboCare Corp. is a high-risk, high-reward biopharmaceutical company focusing on innovative exosome and cellular therapies. Its proprietary ASTEX platform and focus on personalized medicine provide potential advantages. Financial constraints, competition from larger players, and the inherent risks of clinical trials pose significant challenges. The company's success hinges on securing funding, achieving clinical milestones, and successfully commercializing its technologies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Market research reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The data provided is based on available public information and may be subject to change. Invest at your own risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avalon GloboCare Corp.
Exchange NASDAQ | Headquaters Freehold, NJ, United States | ||
IPO Launch date 2016-12-06 | CEO, President & Director Dr. David K. Jin M.D., Ph.D. | ||
Sector Real Estate | Industry Real Estate Services | Full time employees 4 | Website https://www.avalon-globocare.com |
Full time employees 4 | Website https://www.avalon-globocare.com |
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States. It also distributes the KetoAir device, which is a breathalyzer system that detects acetone levels in exhaled breath; and the AI Nutritionist software program that helps users monitor and manage ketogenic diet and related programs. Avalon GloboCare Corp. was founded in 2015 and is headquartered in Freehold, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.